Top Abstract Purchase Related
Home
>
Node
>
Subnode

Contribution to the isolation and study of the molecular weight of human factor VIIi

Mazurier, C.; Parquet-Gernez, A.; Goudemand, M.; Montreuil, J.

Pathologie-Biologie 23 Suppl: 11-16

1975

ISSN/ISBN: 0369-8114
PMID: 57588
Document Number: 90825
The authors describe some properties of highly-purified factor VIII concentrates isolated from human plasma. The fraction containing "factor VIII-complex" (factor VIII procoagulant activity, factor VIII related antigen and von Willebrand factor) is homogeneous by analytical ultra-centrifugation and its sedimentation coefficient is (see article). By gel filtration in high ionic strength buffer a low molecular weight fraction (LMW) with factor VIII procoagulant activity stronger than plasma's one has been isolated. This LMW fraction contains neither factor VIII related antigens nor von Willebrand factor. Its molecular weight determined by gel filtration is approximately 250,000.

Document emailed within 1 workday
Secure & encrypted payments

Bouma, B.N.; Sixma, J.J.; van Mourik, J.A.; Mochtar, I.A. 1973: Low-molecular-weight factor VIIi Lancet 1(7810): 1001
Weiss, H.J. 1973: Low-molecular-weight factor VIIi Lancet 1(7810): 1000
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Lane, J.L.; Ekert, H.; Vafiadis, A. 1979: Affinity chromatography of human factor VIII using human and rabbit antibodies to Factor VIII Thrombosis and Haemostasis 42(4): 1306-1315
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Huber, K.; Kirchheimer, J.; Binder, B.R. 1982: Rapid isolation of high molecular weight urokinase from native human urine Thrombosis and Haemostasis 47(3): 197-202
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Váradi, K.; Rosing, J.; Tans, G.; Schwarz, H.P. 1995: Influence of factor V and factor Va on APC-induced cleavage of human factor VIIi Thrombosis and Haemostasis 73(4): 730-731
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Schäffer, R.; Ormanns, W. 1983: Immunohistochemic detection of factor VIIi antigen in malignant hemangioendotheliomas of the thyroid. a contribution to histogenesis Schweizerische Medizinische Wochenschrift 113(16): 601-605
Lee, C.A.; Owens, D.; Bray, G.; Giangrande, P.; Collins, P.; Hay, C.; Gomperts, E.; Schroth, P.; Barrowcliffe, T. 1999: Pharmacokinetics of recombinant factor VIIi (recombinate) using one-stage clotting and chromogenic factor VIIi assay Thrombosis and Haemostasis 82(6): 1644-1647
Poser, R.; Hirche, H. 1992: Randomized double-blind study of therapy of sudden deafness. Low molecular weight dextran + naftidrofuryl vs. low molecular weight dextran + placebo Hno 40(10): 396-399
Goetzl, E.J.; Rocklin, R.E. 1978: Amplification of the activity of human leukocyte inhibitory factor (LIF) by the generation of a low molecular weight inhibitor of PMN leukocyte chemotaxis Journal of Immunology 121(3): 891-896
Levine, P.H. 1988: Human factor VIII:C purified using monoclonal antibody to von Willebrand factor Seminars in Hematology 25(2 Suppl 1: 1-2